“STAT+: Psilocybin’s lasting benefits prove elusive in mice”

Key points

• UniQure announced FDA accepted marketing application for AMT-130 gene therapy.
• FDA decision date for AMT-130 is set for May 1, 2027.
• FDA tentatively planning advisory committee meeting to review AMT-130 data.
• STAT investigates next-gen IVF business with three-parent IVF and limited evidence.
• Fertility clinics market mitochondrial replacement to older women seeking related children.